Posted by Michael Wonder on 20 Sep 2025
Highlights from the 15-18 September 2025 CHMP meeting
19 September 2025 - The EMA’s CHMP has recommended 14 medicines for approval at its September 2025 meeting.
The committee recommended granting a marketing authorisation for Enflonsia (clesrovimab), a medicine indicated for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants.
